Sinovac Biotech (Sinovac Biotech) Interest Expense : $-0.9 Mil (TTM As of Jun. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sinovac Biotech's interest expense for the six months ended in Jun. 2023 was $ -0.3 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.9 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sinovac Biotech's Operating Income for the six months ended in Jun. 2023 was $ -430.5 Mil. Sinovac Biotech's Interest Expense for the six months ended in Jun. 2023 was $ -0.3 Mil. Sinovac Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinovac Biotech Interest Expense Historical Data

The historical data trend for Sinovac Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech Interest Expense Chart

Sinovac Biotech Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-1.07

-0.65

-1.45

-2.84

-1.26

Sinovac Biotech Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Interest Expense	Get a 7-Day Free Trial															-1.52	-1.31	-0.62	-0.64	-0.26

Sinovac Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.9 Mil.

Sinovac Biotech (NAS:SVA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sinovac Biotech's Interest Expense for the six months ended in Jun. 2023 was $-0.3 Mil. Its Operating Income for the six months ended in Jun. 2023 was $-430.5 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2023 was $51.9 Mil.

Sinovac Biotech's Interest Coverage for the quarter that ended in Jun. 2023 is calculated as

Sinovac Biotech did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Sinovac Biotech (Sinovac Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085

Website

http://www.sinovac.com

Sinovac Biotech Ltd is a biopharmaceutical company. The company focuses on the research, development, manufacturing, and commercialization of vaccines for infectious diseases. Its product portfolio includes vaccines against hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), mumps, and canine rabies. The company also provides services for disease control and prevention, collaborating with the Chinese governments at the national, state, and local levels. It sells its vaccines in China, while also exploring growth opportunities in international markets.

Executives

Lily Wang	director, 10 percent owner, officer: Chief Financial Officer	300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc	10 percent owner	PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong	director, 10 percent owner, officer: President and CEO
Terry G Bowering	director, 10 percent owner, officer: President, CEO	10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6